NanoString Introduces Solution for Simultaneously Measuring miRNA and mRNA Expression Levels

Kit Enables Profiling of Up To 30 miRNAs and 200 mRNAs in a Single Tube without Amplification

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of the nCounter® miRGE Assay for use on its nCounter Analysis System. The nCounter miRGE (“merge”) Assay enables researchers to investigate expression levels of both micro RNAs (miRNAs) and the messenger RNAs (mRNAs) they potentially regulate in a single reaction, without the need for amplification.

The miRGE Assay provides the capacity to perform multiplexed profiling of 5-30 miRNAs and 100-200 mRNAs simultaneously, with specificity and sensitivity comparable to qPCR. Like all nCounter assays, the kit is compatible with multiple sample types, including FFPE samples. The assay is available for human, mouse and rat samples.

"The miRGE Assay is a unique, digital assay that will enable researchers to investigate the interactions between miRNAs and their downstream mRNA targets, all in a single tube,” said Barney Saunders, Chief Commercial Officer for NanoString Technologies. “miRGE delivers highly reproducible results, even for challenging samples such as FFPE tissue, making it ideal for today’s translational research studies.”

The nCounter Analysis System is a fully automated digital detection and counting system with a very simple workflow. The assays contain all of the reagents and consumables required to conduct an experiment. Minimal sample input requirements and compatibility with a variety of sample types, extends the utility of the platform. In addition to miRNA assays, NanoString provides assays for copy number variation and gene expression analysis. The nCounter Analysis System is currently available for Research Use Only.

More information is available at www.NanoString.com.

About NanoString Technologies, Inc.

NanoString Technologies is a privately held provider of life science tools for translational research and developer of molecular diagnostics. The company’s nCounter® Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.

The nCounter platform is for Research Use Only. Not for use in diagnostic procedures.



CONTACT:

for NanoString Technologies, Inc.
Nicole Litchfield, 415-793-6468
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Technology  Nanotechnology  Health  Biotechnology  Genetics  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.